和铂医药-B中期报告2023

中 報2023 2478113044454648495178 P.O. Box 472, Harbour Place, 2nd Floor103 South Church Street, George TownGrand Cayman KY1-1106Cayman Islands Robert Irwin KamenAlbert R. Collinson 218A3202 3485 International Corporation Services Ltd.P.O. Box 472, Harbour Place, 2nd Floor103 South Church Street, George TownGrand Cayman KY1-1106, Cayman Islands Robert Irwin Kamen 1617 97927 201623 www.harbourbiomed.com 02142 HarbourTherapeutics HBM9161HBM4003HBM7008HBM1020 (HBM9161) FcRnFcRnIgGIgGFcRnbatoclimabbatoclimab (HBM4003) HBM4003CTLA-4T4(CTLA-4)THCAbHBM4003CTLA-4CTLA-4CTLA-4HBM4003TPK(ADCC)HBM4003TregHBM4003HBM4003 HBM7008 HBM7008B7H44-1BBTTHBM7008HBICE®PD-L1PD1/PD-L14-1BB HBM1020 HBM1020Harbour Mice®B7H7B7B7H7PD-L1HBM1020B7H7B7H7PD-L1PD-(L)1PD-L1B7H7HBM1020 HBM1022(CCR8)HBM1007CD73HBM9378TSLPHBM1047CD200R1HBICE®HBM7020(BCMAxCD3)HBM9027(PD-L1xCD40),HBM7022 (CLDN18.2xCD3), HBM7004 (B7H4xCD3)Harbour Mice®HBM9033MSLNADC HBM4003Harbour Mice®Harbour Mice®(H2L2)(HCAb)H2L2(H2L2)HCAbmRNAADCHCAbHBICE®HCAbHCAbPlusTMB I to ITMINDHarbourMice®B HarbourTherapeutics50 HarbourMice®HCAb PlusTMI to ITM HARBOUR THERAPEUTICS 1.(HBM9161) a.gMGIIIb.gMGBLANMPA 2.(HBM4003) PD-1HCC a.(ASCO)(HCC)Ib PD-1NET/NEC b.(AACR)NENIb 3.HBM9378 a.I 4.HBM1020 a.FDAINDIb.I 5. a.HBM1007FDAINDIb.HBM1022FDAINDI 1. a.HBM7022HBICE®FDANMPAINDIb.Cullinan Oncology Inc.CullinanCullinanHBM7008c.IND 2. a.HarbourMice®b.ADCADCc.M y t h i cT h e r a p e u t i c sM y t h i cTherapeuticsADCd.(mAbs)(WEEV)(SFTSV)e.(PIRC)Harbour Mice®f.OPKO HealthModeX TherapeuticsModeX 3. a.HBM Alpha TherapeuticsHBMAT HARBOUR THERAPEUTICS HarbourTherapeutics HarbourMice®(H2L2)(HCAb)HCAb(HBICE®)B I to ITMINDHarbourMice®B HarbourTherapeutics HARBOUR THERAPEUTICS (HBM9161) gMGIIIIIIgMG(HBM9161)gMGBLANMPANMPABLAHBM9161 (HBM4003) HBM4003HCAbCTLA-4HBM4003NET/NECHCC PD-1NET/NEC A.AACR(HBM4003)Ib IbHBM4003NEN(PK)(PD)NEN(pts)(Q3W)0.3mg/kg0.45mg/kg+240mg(RECIST)1.1(ORR) –NEN –(ORR)(DCR)38.9%61.1%3(DOR)80%DOR –NECORRDCR38.5%69.2% PD-1HCC B.ASCO(HBM4003)HCCIb IbHBM4003HCC(PK)(PD)12HCC(n=28)(Q3W)0.45mg/kg+240mg1VEGFRPD-(L)1(n=16)2PD-(L)1VEGFR(n=12)RECIST 1.1(ORR) 115ORR(DCR)46.7%73.3% 211ORRDCR9.1%RECIST18.2%54.5% 1Treg HBM9378 HBM9378HBM9378 H B M9378H2L2TSLPTSLPTSLPDCT helper 2 (Th2)HBM9378HBM9378 HBM9378I HBM1020 HBM1020H2L2B7H7 B7H7HHLA2B7B7TB7PD-(L)1CTLA-4B7B7B7H7PD-L1PD-L1PD-(L)1PD-L1B7H7 INDI IND 1.HBM1022 HBM1022G(GPCR)CCR8CCR8TTHBM1022CCR8 CCR8TregG(GPCR)GPCRCCR8TregTTreg HBM1022CCR8GPCRHBM1022CCR8T HBM1022FDAINDI 2.HBM1007 HBM1007H2L2CD73CD73(AMP)CD73HBM1007CD73AMP(TME)CD73CD73 HBM1007FDAINDI 3.HBM9033 HBM9033(ADC)MSLNHBM9033HarbourMiceMSLN(sMSLN)MSLNADCHBM9033MSLNHBM9033I 4.HBM9027 HBM9027PD-L1×CD40HBICE®HarbourMice®PD-L1×CD40PD-L1×CD40HBICE®DCHBICE® •PD-1/PD-L1CD40•T• •CD40CD40 •T 5.HBM7004 HBM7004B7H4xCD3HBICE®(H2L2HCAb)B7H4xCD3HBICE®HBICE® •B7H4B7H4T•CD3•TMHC-TCR••B7H4x4-1BB 6.HBM9014 HBM9014(LIFR) •LIFRIL6IL6 •• 7.HBM1047 HBM1047CD200R1(H2L2)HBM1047CD200R1THBM1047CD200CD200R1 •HBM1047CD200R1•HBM1047T•HBM1047•HBM1047PK•HBM1047200mg/kg HARBOUR THERAPEUTICS HarbourTherapeutics 1.HBM7022 HBM7022HBM7022HBICE®FDANMPAINDI 2.HBM7008Cullinan Oncology CullinanCullinanHBM7008 3. HBM1029HBM7015HBM7020INDI 4. HBMATHBMATHBM9013CMC IdeaIND 25 1. HarbourMice®HarbourMice® 2. ADCADC 3.Mythic Therapeutics MythicTherapeuticsMythicTherapeutics(ADC)Mythic Therapeutics(HCAb)Mythic TherapeuticsFateControl™ 4. MichaelS.Diamond(mAbs)(WEEV)(SFTSV) 5.PIRC (PIRC)Harbour Mice®H2L2HCAb 6.ModeX Therapeutics OPKO HealthModeX TherapeuticsModeXModeXHarbourMice®ModeXMSTAR •AACR(HBM4003)NET/NECIb •ASCO(HBM4003)HCCIb HarbourTherapeutics •26812174 ADCGPCRmRNA 18A.08(3) 5% NKNK15.8%15.8%A11.75% 6.132.74% HarbourTherapeuticsHBM4003HBM1020INDHarbourMice®HBICE® ADC12130%3030%1,30030%30% 41.02.927.673.1 3.22.828.483.68.615.3 27.641.027.139.50.51.5 0.020.07 3.22.8 83.628.4(i)(ii)17.78.8 6.88.610.85.5 73.176.02.9 (2) (3) 0.60.7 80.92.1 15115 14.42.928.56.9 14 C.2.1 C.2.1 10 13.51B(1) Albert. R. Collinson Albert.R.Collinson653020097CollinsonTheracos,Inc.2Collinson200920146OpsonicTherapeuticsCollinson20042009Rib-X Pharmaceuticals20002004Phylos, Inc.19982000BASFPharmaCollinsonImmunoGen, Inc. Collinson19871980Collinson 13.51B(1) 138,221,0001,656.6HBM9161 XVXV78352 (1)768,428,910(2)HARBOURBIOLLCSouth Dakota Trust Company LLCHARBOURBIO LLC 99.96%(3)3,381,0002,328,000Kastle Limited(4)Kamen2,625,9601,502,080KamenShuxin Biotech Limited(5)435,000281,000Kastle Limited XVXV78352 XV23336 (1)LS(2)768,428,910(3)AdvantechMaster Investment LimitedAdvantechMaster Investment Limited AdvantechCapitalL.P.AdvantechCapitalAdvantech CapitalAdvantechCapital Holdings Ltd.Advantech Capital Partners Ltd.Advantech Capital Holdings Ltd.Advantech Master Investment LimitedAdvantech Capital Advantech Capital Partners Ltd.Advantech Capital Holdings Ltd.2,339,034(4)LC Fund GP LimitedLC FundGP LimitedLC H